Hussein Sweiti
Equibles does not estimate personal net worth.
About Hussein Sweiti
enGene Therapeutics Inc. reported in an 8-K filed June 15, 2026 that Hussein Sweiti resigned as Chief Medical Officer and Head of Research and Development, effective June 14, 2026. The proxy statement of enGene Therapeutics Inc. reports total compensation of $3,151,902 for Hussein Sweiti in fiscal 2025, including a base salary of $43,750.
“On June 13, 2026, Dr. Hussein Sweiti notified the Company of his resignation from his position as Chief Medical Officer and Head of Research and Development of the Company, with his resignation to be effective as of June 14, 2026.”
Affiliation history
-
enGene Therapeutics Inc. (ENGN)
Proxy statement
Start not stated–2026-06-14
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | enGene Therapeutics Inc. (ENGN) | Chief Medical Officer | $43,750 | $3,151,902 |